Aureus Asset Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.5M | Buy |
6,899
+98
| +1% | +$21.7K | 0.1% | 90 |
|
|
2025
Q4 | $1.55M | Buy |
6,801
+75
| +1% | +$17.1K | 0.1% | 81 |
|
|
2025
Q3 | $1.56M | Sell |
6,726
-254
| -4% | -$51.7K | 0.1% | 77 |
|
|
2025
Q2 | $1.3M | Buy |
6,980
+15
| +0.2% | +$2.79K | 0.08% | 86 |
|
|
2025
Q1 | $1.46M | Buy |
6,965
+112
| +2% | +$21.8K | 0.1% | 81 |
|
|
2024
Q4 | $1.22M | Buy |
6,853
+3,950
| +136% | +$726K | 0.08% | 86 |
|
|
2024
Q3 | $573K | Sell |
2,903
-240
| -8% | -$44.8K | 0.04% | 117 |
|
|
2024
Q2 | $539K | Buy |
3,143
+428
| +16% | +$70.9K | 0.04% | 114 |
|
|
2024
Q1 | $494K | Buy |
2,715
+14
| +0.5% | +$2.41K | 0.03% | 125 |
|
|
2023
Q4 | $419K | Sell |
2,701
-53
| -2% | -$7.73K | 0.03% | 131 |
|
|
2023
Q3 | $411K | Sell |
2,754
-326
| -11% | -$47.9K | 0.03% | 130 |
|
|
2023
Q2 | $415K | Buy |
3,080
+486
| +19% | +$71.3K | 0.03% | 129 |
|
|
2023
Q1 | $413K | Hold |
2,594
| – | – | 0.03% | 129 |
|
|
2022
Q4 | $419K | Buy |
2,594
+507
| +24% | +$77.7K | 0.04% | 130 |
|
|
2022
Q3 | $280K | Buy |
2,087
+19
| +0.9% | +$2.73K | 0.02% | 145 |
|
|
2022
Q2 | $317K | Buy |
2,068
+805
| +64% | +$123K | 0.03% | 156 |
|
|
2022
Q1 | $205K | Buy |
+1,263
| New | +$183K | 0.01% | 208 |
|
|
2021
Q1 | – | Sell |
-2,089
| Closed | -$224K | – | 178 |
|
|
2020
Q4 | $224K | Buy |
+2,089
| New | +$201K | 0.02% | 171 |
|
|
2020
Q3 | – | Sell |
-2,269
| Closed | -$223K | – | 178 |
|
|
2020
Q2 | $223K | Buy |
+2,269
| New | +$200K | 0.02% | 153 |
|
|
2018
Q2 | – | Sell |
-3,857
| Closed | -$365K | – | 187 |
|
|
2018
Q1 | $365K | Buy |
3,857
+363
| +10% | +$39.9K | 0.05% | 127 |
|
|
2017
Q4 | $338K | Hold |
3,494
| – | – | 0.05% | 138 |
|
|
2017
Q3 | $310K | Buy |
3,494
+200
| +6% | +$15.2K | 0.05% | 139 |
|
|
2017
Q2 | $239K | Sell |
3,294
-312
| -9% | -$21K | 0.04% | 146 |
|
|
2017
Q1 | $235K | Buy |
+3,606
| New | +$227K | 0.04% | 157 |
|
|
2016
Q4 | – | Sell |
-3,265
| Closed | -$206K | – | 162 |
|
|
2016
Q3 | $206K | Buy |
+3,265
| New | +$211K | 0.04% | 142 |
|
|
2015
Q4 | – | Sell |
-7,897
| Closed | -$430K | – | 147 |
|
|
2015
Q3 | $430K | Buy |
7,897
+554
| +8% | +$36.1K | 0.11% | 91 |
|
|
2015
Q2 | $493K | Buy |
7,343
+3,411
| +87% | +$223K | 0.1% | 98 |
|
|
2015
Q1 | $230K | Buy |
+3,932
| New | +$238K | 0.05% | 134 |
|
Other funds holding ABBV
VCM
VPM
Aureus Asset Management's ABBV Position: Q1 2026 in Review
Aureus Asset Management increased its AbbVie (ABBV) stake by 1.4% in Q1 2026, buying an estimated $21.7K and bringing the position to 6,899 shares worth $1.5M. The position accounts for 0.1% of the portfolio, ranked #90.
Aureus Asset Management first reported a position in ABBV in Q1 2015 and has held it in 28 quarters since. The position peaked at $1.56M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Aureus Asset Management held 6,899 shares of AbbVie worth $1.5M as of Q1 2026.
- Aureus Asset Management bought 98 AbbVie shares in Q1 2026, an estimated $21.7K.
- AbbVie made up 0.1% of Aureus Asset Management's portfolio in Q1 2026, its #90 holding.
- Aureus Asset Management first reported a position in AbbVie in Q1 2015 and has held it in 28 quarters since.
- Aureus Asset Management's AbbVie position peaked at $1.56M in Q3 2025.
- 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Aureus Asset Management's 13F filing for Q1 2026, filed 13 May 2026.